NCT04957615 2026-04-15
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT04317105 2026-04-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05219435 2025-09-24
VEXILLUM
Spanish Oncology Genito-Urinary Group
Phase 2 Active not recruiting
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT03525925 2024-03-18
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
NCT03453892 2023-02-16
ST-ICI
University of Erlangen-Nürnberg Medical School
Completed
NCT04761744 2021-02-21
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
Phase 2 Unknown
NCT03119428 2020-08-11
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma
Phase 1 Terminated
NCT03864575 2019-07-12
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown